Triptorelin (Trelstar)
Overview
Triptorelin is a synthetic decapeptide analogue of gonadotropin-releasing hormone (GnRH) that functions as a long-acting GnRH agonist. Following an initial stimulatory phase, chronic administration leads to downregulation of pituitary GnRH receptors, resulting in suppression of luteinizing hormone and follicle-stimulating hormone secretion and subsequent reduction in sex steroid production.
Mechanism of Action
This mechanism provides therapeutic benefit in hormone-sensitive conditions including advanced prostate cancer, endometriosis, and central precocious puberty. The peptide incorporates amino acid substitutions at positions 6 and 10 to enhance receptor affinity and metabolic stability.
Research Summary & Key Findings
Triptorelin received FDA approval in 2000 for palliative treatment of advanced prostate cancer, with pivotal trials demonstrating effective castration in over 90% of patients maintained on depot formulations. Comparative studies have shown equivalent efficacy to other GnRH agonists such as leuprolide and goserelin in achieving and maintaining testosterone suppression. Long-term extension studies have confirmed durability of response with acceptable tolerability profiles across approved depot formulations (1-month, 3-month, and 6-month).
Clinical Status
Triptorelin (Trelstar) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.
Administration Routes
References
Primary literature
- PubMed — "Triptorelin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov — "Triptorelin"
Registered interventional and observational studies, including status and phase.
- PubChem — "Triptorelin"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Oncology
Carfilzomib (Kyprolis)
FDA ApprovedA tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds the chymotrypsin-like (beta5) subunit of the 20S...
View detailsBortezomib (Velcade)
FDA ApprovedA modified dipeptidyl boronic acid that reversibly inhibits the chymotrypsin-like activity of the 26S proteasome. Bortez...
View detailsLutetium-177 dotatate (Lutathera)
FDA ApprovedA radiolabeled somatostatin analog consisting of the peptide DOTA-Tyr3-octreotate chelated to the beta-emitting radioiso...
View detailsLeuprolide (Lupron) - Oncology
FDA ApprovedA GnRH agonist used in oncology for androgen deprivation therapy (ADT) in prostate cancer and hormone suppression in pre...
View detailsStart Your Consultation
Get an AI-proposed Triptorelin (Trelstar) protocol reviewed by a physician in our network.
Start Your ConsultationFind a Pharmacy
Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Triptorelin (Trelstar).
Pharmacy DirectoryJoin the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.